BioNTech SE (BNTX)
BioNTech: Maintaining "Strong Buy" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart
BioNTech (BNTX) maintains a "Strong Buy" rating, driven by positive phase 3 data for gotistobart in 2nd-line squamous NSCLC patients. BNTX's gotistobart delivered a 63.1% 12-month OS rate versus 30.3% for docetaxel, reducing risk of death by 54%. Upcoming pivotal phase 3 PRESERVE-003 data in 2026 and expansion into ovarian and prostate cancers offer significant pipeline catalysts.
FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks
A report that vaccine approvals could be set to get stricter is pressuring shares of major vaccine makers.
BioNTech SE (BNTX) Discusses Oncology Innovation Strategy, Combination Therapies and Personalized Cancer Immunotherapies Transcript
BioNTech SE ( BNTX ) Discusses Oncology Innovation Strategy, Combination Therapies and Personalized Cancer Immunotherapies November 11, 2025 9:00 AM EST Company Participants Ugur Sahin - Co-Founder, CEO & Chair of the Management Board Özlem Türeci - Co-Founder, Chief Medical Officer & Member of Management Board Ilhan Celik Michael Wenger Ramón Zapata-Gomez - CFO & Member of Management Board Douglas Maffei - Vice President of Strategy & Investor Relations Annemarie Hanekamp - Chief Commercial Officer & Member of Management Board Conference Call Participants Daina Graybosch - Leerink Partners LLC, Research Division Tazeen Ahmad - BofA Securities, Research Division Jay Lee - Morningstar Inc., Research Division Akash Tewari - Jefferies LLC, Research Division Terence Flynn - Morgan Stanley, Research Division William Maughan - Clear Street LLC., Research Division Jae-Young Park Malcolm Hoffman - BMO Capital Markets Equity Research Asthika Goonewardene - Truist Securities, Inc., Research Division William Zhang Presentation Unknown Executive [Audio Gap] by Annemarie Hanekamp, our Chief Commercial Officer.
BioNTech Q3 Earnings: Plenty Of Cash And Pipeline Potential, But Still A Hold
BioNTech SE shared its Q3 earnings, business updates, and guidance for 2025 earlier today. Its share price is down 1% in trading so far. BNTX maintains a strong cash position, driven by ongoing Comirnaty COVID vaccine sales and significant upfront payments from Bristol-Myers Squibb. BNTX's oncology pipeline, led by pumitamig, is progressing but lacks best-in-class data or approvals, making future revenue potential uncertain.
BioNTech SE (BNTX) Q3 2025 Earnings Call Transcript
BioNTech SE ( BNTX ) Q3 2025 Earnings Call November 3, 2025 8:00 AM EST Company Participants Douglas Maffei Ugur Sahin - Co-Founder, CEO & Chair of the Management Board Özlem Türeci - Co-Founder, Chief Medical Officer & Member of Management Board Ramón Zapata-Gomez - CFO & Member of Management Board Conference Call Participants Tazeen Ahmad - BofA Securities, Research Division Terence Flynn - Morgan Stanley, Research Division Daina Graybosch - Leerink Partners LLC, Research Division Nick Jennings - Goldman Sachs Group, Inc., Research Division Manoj Eradath - Jefferies LLC, Research Division Yaron Werber - TD Cowen, Research Division Mohit Bansal - Wells Fargo Securities, LLC, Research Division Malcolm Hoffman - BMO Capital Markets Equity Research Mario Joshua Chazaro Cortes - Evercore ISI Institutional Equities, Research Division Jay Olson - Oppenheimer & Co. Inc., Research Division Presentation Operator Welcome to BioNTech's Third Quarter 2025 Earnings Call. I will now hand the call over to Doug Maffei, Vice President, Strategy and Investor Relations.
BioNTech lifts 2025 revenue guidance on BMS partnership payment
Germany's BioNTech on Monday lifted its 2025 revenue guidance after receiving initial payments from its new partner Bristol Myers Squibb in a cancer immunotherapy alliance that seeks to challenge Merck's best-selling Keytruda.
BioNTech SE (BNTX) Q2 2025 Earnings Call Transcript
BioNTech SE (NASDAQ:BNTX ) Q2 2025 Earnings Conference Call August 4, 2025 8:00 AM ET Company Participants Douglas Maffei - Investor Relations Ozlem Tureci - Co-Founder, Chief Medical Officer & Member of Management Board Ramón Zapata-Gomez - CFO & Member of Management Board Ryan Richardson - Chief Strategy Officer, MD & Member of Management Board Ugur Sahin - Co-Founder, CEO & Chair of the Management Board Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Asad Haider - Goldman Sachs Group, Inc., Research Division Cory William Kasimov - Evercore Inc. Daina Michelle Graybosch - Leerink Partners LLC, Research Division Jessica Macomber Fye - JPMorgan Chase & Co, Research Division Tazeen Ahmad - BofA Securities, Research Division Terence C. Flynn - Morgan Stanley, Research Division Operator Welcome to BioNTech Second Quarter 2025 Earnings Call.
BioNTech's Q2 revenues double on higher COVID vaccine sales
German biotech firm BioNTech on Monday said that second-quarter revenues more than doubled to 261 million euros ($302 million), driven by higher revenues from its COVID-19 vaccine collaboration with Pfizer.
BioNTech SE Sponsored ADR (BNTX) Is Up 4.81% in One Week: What You Should Know
Does BioNTech SE Sponsored ADR (BNTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Best Momentum Stocks to Buy for July 29th
GDS, U and BNTX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 29, 2025.
Has BioNTech (BNTX) Outpaced Other Medical Stocks This Year?
Here is how BioNTech SE Sponsored ADR (BNTX) and EUROFINS SCIENT (ERFSF) have performed compared to their sector so far this year.
BioNTech boosts cancer mRNA pipeline with CureVac acquisition
BioNTech (NASDAQ:BNTX) announced that it is acquiring CureVac (NASDAQ:CVAC), a fellow German mRNA vaccine developer, in an all-stock deal valued at approximately $1.25 billion. Under the deal terms, each share of CureVac will be exchanged for about $5.46 worth of BioNTech American Depositary Shares (ADSs), representing a premium of around 55% over CureVac's recent trading price.
